881 / 1109
Conclusions
Margin-less treatment planning is feasible
E
qual or higher target coverage
Equal or lower dosage to OARs
Small increase in optimization time
Reduced number of objective functions
No boost volume with smaller margin required
Potentially solves the buildup problem if you evaluate
multiple anatomies, dose is never evaluated outside the
tumor
Open issues:
Vendors, implement it!
25